Published on: April 1, 2026
If you've been following the GLP-1 space at all — and at this point, who hasn't — you've probably heard the news: there's now an oral semaglutide option. A pill. No injection. The headlines have been buzzy, the marketing has been enthusiastic, and plenty of patients have asked me about it. So I sat down with Dr. Randi Lindstrom, who prescribes GLP-1s regularly in at Glow, to break it all down honestly.
The short version: the Ozempic pill is interesting, it has a narrow use case, and for most people it's probably not the right choice — at least not yet. But there's a lot of nuance in the "why," and there's also genuinely exciting new data on long-term GLP-1 use that I want to share. Let's get into it.
The reason Botox, semaglutide, and basically every other peptide-based drug has historically been an injection is simple biology. GLP-1 is a string of amino acids — it's essentially a small protein. And when you eat protein, your stomach digests it. It doesn't absorb it whole. This is also why eating collagen supplements doesn't give you the same effect as an injectable — your GI tract just breaks the whole molecule apart before it can do anything useful.
So for years, making an oral GLP-1 has been the holy grail. What Novo Nordisk has done with oral semaglutide is attach a special absorption-enhancing molecule to the drug — one that helps it survive the stomach environment and get absorbed intact. It's called the SNAC model (Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, if you want the full mouthful). Basically, it buffers the pH around the drug in the stomach, creating a microenvironment where the peptide can cross the stomach lining without being destroyed.
Clever chemistry. Real science. And it works — to a point.
The oral pill has to be taken on a completely empty stomach — first thing in the morning — with no more than four ounces of water. Then you have to wait at least 30 minutes before eating or drinking anything else. The reason is that the absorption mechanism is very sensitive to stomach pH, and more fluid or food dilutes that environment and dramatically reduces how much drug gets absorbed.
For a lot of people, this sounds manageable. But consider: a huge number of women (and men) over 40 take thyroid medication, which has its own fasting and timing requirements. I've been on thyroid medication for most of my adult life. The standard protocol is: take it on an empty stomach, wait 30 minutes, then eat. If you're now adding oral semaglutide to the same morning routine, you're looking at two separate fasting windows stacked on top of each other — or you're shuffling your thyroid dose to the evening, which comes with its own absorption adjustments. It becomes a whole production, every single day.
Oral bioavailability of semaglutide is significantly lower than injectable, and — unlike thyroid, where we can check your TSH to confirm you're at the right level — there's no simple blood test to confirm you're absorbing your GLP-1 at a therapeutic level. This makes dosing less predictable compared to injectable forms.
This is the math that makes the "affordable" marketing a bit misleading. The starting dose of oral semaglutide is 3mg daily, scaling up to 25mg. By comparison, the injectable maxes out at 2.4mg weekly. To match what someone is already getting from a 2.4mg injection, you'd need roughly 25mg of the oral form daily. That's not a $149/month treatment. The $149 price point applies to the lowest starting dose — which is essentially a micro-dose that's not really therapeutic. Insurance coverage for the oral form is also largely not yet in place.
One of the reasons many patients and physicians have shifted from semaglutide to tirzepatide (Zepbound/Mounjaro) over time is that tirzepatide tends to have a more favorable side effect profile — less nausea, better tolerability — with greater weight loss. The oral pill actually moves in the opposite direction: because you're delivering the drug directly through the GI tract, it seems to increase GI side effects compared to injectable semaglutide. So if you're already struggling with nausea on the injectable and thinking the pill might be easier — it very likely won't be.
Head-to-head studies show a modest but real reduction in efficacy compared to injectable semaglutide. Not dramatic, but it's there.
Honestly, it's a narrow group. The most compelling use case is someone who is genuinely needle-phobic — not just mildly uncomfortable with injections, but unable or unwilling to do them even with coaching. At Glow, we have had patients who couldn't bring themselves to inject at home and needed someone to do it for them every week. For that person, the pill may be the difference between treatment and no treatment.
It could also be reasonable as a starting option for someone who has never been on a GLP-1 before, is fine with the dosing logistics, has no thyroid medication conflicts, and wants to try the lowest-stakes entry point first.
But for most people who are candidates for a GLP-1 — especially those who have already been on semaglutide or tirzepatide — the oral pill isn't an upgrade. I'd still put tirzepatide injectable at the top of my personal preference list: fewer side effects, better efficacy, and a well-established track record.
This is the question I get more than almost any other from patients, and there's finally a well-designed study addressing it. The SURMOUNT-4 regain study looked at people on tirzepatide for 36 weeks — specifically patients with a BMI over 30, or over 27 with an obesity-related condition like diabetes. That group lost an average of 21% of their body weight on tirzepatide. Remarkable. Then they were split: half continued tirzepatide, half were switched to placebo for another 52 weeks.
Here's what happened:
The group that continued tirzepatide lost an additional 5.5% of body weight on average. The group that stopped — well, it was more complicated.
What this tells me is that this is highly individual. For people with genuine metabolic disease — obesity as a chronic condition with insulin resistance, elevated cardiovascular risk, and so on — stopping cold turkey is likely to result in significant weight regain for the majority. These patients should probably think of GLP-1 therapy the way we think about blood pressure medication: an ongoing tool for managing an ongoing condition, not a short course.
But not everyone fits that profile. Some people — maybe those who have been overweight for less time, whose metabolisms respond differently, or who use the medication period to build new habits and muscle — do seem to maintain their results after stopping. We just can't predict in advance which category you'll fall into.
What most experienced physicians are doing in practice: Rather than stopping abruptly, we're extending the interval between doses to find a maintenance cadence. Some patients do well injecting every two weeks. Some every three. Some every four. I'm one of them — I lost weight on the lowest dose of tirzepatide and now inject roughly every three weeks, and I've been stable for about a year. The goal is to find the minimum dose and frequency that keeps your weight and metabolic markers where you want them.
Beyond weight loss, the evidence on GLP-1s is accumulating in genuinely exciting directions.
We've known for a while that excess visceral fat — the fat wrapped around your organs — drives cardiovascular risk. What the longer-term studies are confirming is that GLP-1s reduce blood pressure, improve metabolic markers, and lower the risk of heart attack and stroke. Worth noting: if you stop and regain the weight, these benefits largely go with it. But for people staying on maintenance, the cardiovascular data is compelling.
This one surprised even me when we started digging into it. Observational studies are showing reduced risk across 13 types of obesity-related cancers — including postmenopausal breast cancer, colorectal, pancreatic, and esophageal cancers. These cancers are linked to obesity partly through chronic inflammation, elevated insulin-like growth factors, and hormonal dysregulation. The really interesting emerging question is whether the GLP-1 receptor signaling itself — separate from weight loss — is playing a role in reducing cancer risk and recurrence. The research is ongoing, but the early signals are striking.
GLP-1s appear to lower markers of systemic inflammation — CRP and other indicators — which is translating into real reductions in arthritis symptoms for some patients. This isn't fully understood yet, but it tracks with the drug's broader metabolic effects.
This one gets overlooked, but it matters enormously for a subset of patients. Women with PCOS — polycystic ovary syndrome — often have underlying insulin resistance that disrupts their hormonal signaling, leading to irregular or absent menstrual cycles and difficulty getting pregnant. GLP-1s improve insulin sensitivity, which appears to help restore regular ovulation. We're seeing real-world reports of women who assumed they couldn't conceive getting pregnant on semaglutide — the so-called "Ozempic babies." If you're on a GLP-1 and not planning pregnancy, be aware that fertility may increase. And note that GLP-1s may also reduce the effectiveness of oral contraceptives, since those are absorbed through the GI tract.
I want to briefly mention retatrutide — a next-generation drug that is not FDA-approved yet but coming soon, so I'll keep this brief. If semaglutide is a GLP-1 receptor agonist (one mechanism), and tirzepatide adds a GIP receptor component (two mechanisms), retatrutide adds a third — glucagon receptor agonism. The thinking is that targeting more pathways simultaneously could produce better results or fewer side effects. Whether it delivers on that promise is something we'll be watching closely. We'll have a full episode on it once there's more data and real-world experience
I'm going to be honest: I was not always a big proponent of pharmaceutical weight loss interventions. I'm a physician who prefers conservative, lifestyle-based approaches first. But GLP-1s have genuinely changed my thinking.
The data is too good to dismiss. We tried telling people to eat more broccoli and exercise more for decades. For many people, it just doesn't work — not because they lack willpower, but because the underlying metabolic biology is working against them. These drugs address that in a real way.
The pill? It's not where I'd start, and it's not going to be the right answer for most people. But the bigger story here is that the GLP-1 toolkit keeps getting better, the evidence for long-term benefit keeps accumulating, and for the right patient with the right provider, these drugs are genuinely transformative.
As always: work with a physician who actually knows these medications, who's going to individualize your plan, who checks in on your muscle mass and protein intake, and who isn't just handing you a prescription and sending you on your way. The drug is a tool. What you do with it — the resistance training, the protein, the follow-up — is what makes the difference long-term.
More updates to come as the data evolves.
If you're considering GLP-1 treatment and want guidance on the right option — including whether injectables or oral medications make more sense — a consultation can help you make a more informed decision based on your goals and medical history.
Kate Dee, MD is the Founder and CEO of The MedSpa Board and the Founder of Glow Medispa in Seattle. The information discussed in this post was drawn in part from a conversation with Dr. Randi Lindstrom on The MedSpa Confidential Podcast. This is for educational purposes only and is not medical advice.
